Leerink Swann Downgrades Warner Chilcott (WCRX) to Market Perform

Go back to Leerink Swann Downgrades Warner Chilcott (WCRX) to Market Perform

Actavis (ACT) Fairly Valued After Run-Up - Jefferies

May 21, 2013 8:59 AM EDT

Jefferies raised its price target Actavis (NYSE: ACT) from $120 to $133 following the Warner Chilcott plc (NASDAQ: WCRX) takeover announcement, but maintained a Hold rating on the shares.

Analyst Corey Davis, Ph.D. comments, "ACT buying WCRX... More

Susquehanna Downgrades Warner Chilcott (WCRX) to Neutral

May 21, 2013 7:26 AM EDT

Susquehanna downgraded Warner Chilcott (NASDAQ: WCRX) from Positive to Neutral with a price target of $21.00.

For an analyst ratings summary and ratings history on Warner Chilcott click here. For more ratings news on Warner Chilcott click here.

Shares of Warner Chilcott closed at $19.60 yesterday, with a 52 week range of $10.85-$20.51.... More

Warner Chilcott (WCRX) / Actavis (ACT) Deal Features $160M Termination Fee

May 20, 2013 4:56 PM EDT

This Actavis, Inc. (NYSE: ACT) and Warner Chilcott plc (NASDAQ: WCRX) announced they have entered into a definitive agreement under which Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. According to filings, the deal has a $160 million termination fee.

From Filing: "The Transaction Agreement contains... More

UPDATE: Lazard Capital Downgrades Warner Chilcott (WCRX), Says Deal Could Fall Through

May 20, 2013 11:01 AM EDT

(Updated - May 20, 2013 11:43 AM EDT)

Lazard Capital downgraded Warner Chilcott (NASDAQ: WCRX) from Buy to Neutral. This morning it was learned that Actavis (NYSE: ACT) entered into a definitive agreement under which Actavis will acquire Warner Chilcott in a... More

Valeant (VRX), Mylan (MYL) on Watch as Actavis (ACT) Buys Warner Chilcott (WCRX)

May 20, 2013 7:16 AM EDT

Valeant Pharmaceuticals (NYSE: VRX) and Mylan (NYSE: MYL), both potential suitors for Actavis, Inc. (NYSE: ACT) are on watch after Actavis announced its own $8.5 billion deal for Warner Chilcott plc (NASDAQ: WCRX) today.... More

Actavis (ACT) to Acquire Warner Chilcott (WCRX) in $8.5B Deal

May 20, 2013 7:08 AM EDT

Actavis, Inc. (NYSE: ACT) and Warner Chilcott plc (NASDAQ: WCRX) today announced they have entered into a definitive agreement under which Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. If successfully completed, the transaction will create a leading global specialty pharmaceutical company with approximately $11 billion in combined annual revenue, and the third-largest U.S. specialty pharmaceutical company with approximately $3 billion in annual revenues focused on core therapeutic categories of Women's Health, Gastroenterology, Urology and Dermatology. The proposed transaction has been unanimously... More

Warner Chilcott plc (WCRX) Halted News Pending

May 20, 2013 7:02 AM EDT

Warner Chilcott plc (Nasdaq: WCRX) Halted News Pending... More